734
Participants
Start Date
March 31, 2010
Primary Completion Date
October 31, 2011
Study Completion Date
October 31, 2011
Levomilnacipran ER
Drug: Levomilnacipran ER (40, 80 or 120 mg/day) Study drug is to be given orally, in capsule form, once daily.
Placebo
Matching placebo to be given orally, in capsule form, once daily.
Forest Investigative Site #011, Staten Island
Forest Investigative Site #008, Bridgeville
Forest Investigative Site #020, Philadelphia
Forest Investigative Site #028, Norristown
Forest Investigative Site #013, Baltimore
Forest Investigative Site #014, Atlanta
Forest Investigative Site #017, Encino
Forest Investigative Site #029, Maitland
Forest Investigative Site #016, Orlando
Forest Investigative Site #004, South Miami
Forest Investigative Site #005, North Miami
Forest Investigative Site #015, Fort Myers
Forest Research Institute #001, Bonita Springs
Forest Investigative Site #024, Memphis
Forest Investigative Site #022, Chicago
Forest Investigative Site #006, Chicago
Forest Investigative Site #012, St Louis
Forest Investigative Site #009, Prairie Village
Forest Investigative Site #007, Dallas
Forest Investigative Site #019, San Antonio
Forest Investigative Site #023, Beverly Hills
Forest Investigative Site #003, Sherman Oaks
Forest Investigative Site #002, San Diego
Forest Investigative Site #025, Newport Beach
Forest Investigative Site #021, Garden Grove
Forest Investigative Site #030, Orange
Forest Investigative Site #026, Portland
Forest Investigative Site #018, Bellevue
Forest Investigative Site #027, Seattle
Forest Investigative Site #010, Boston
Forest Investigative Site #050, Kelowna
Forest Investigative Site #051, Vancouver
Forest Investigative Site #052, Sydney
Forest Investigative Site #055, Chatham
Forest Investigative Site #053, Ottawa
Lead Sponsor
Forest Laboratories
INDUSTRY